Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised TD Cowen and the placement agents in connection with Harpoon Therapeutics’ offering. Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised the underwriters in connection with Lexeo Therapeutics’ IPO. Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming...
You must be a Standard 1 Year member to access this content.
Cooley advised CymaBay, and Paul Hastings advised the representatives of the underwriters. CymaBay Therapeutics, Inc. announced its $258.75 million follow-on offering of common stock and pre-funded...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the initial purchasers on the deal. Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Maples and Calder represented Social Capital Suvretta Holdings Corp. I in the transaction. Goodwin Procter advised Akili, while Skadden, Arps,...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Exscientia on the deal while Goodwin Procter represented Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities and Barclays Capital...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
You must be a Standard 1 Year member to access this content.
